Page last updated: 2024-11-07

prednisone and Thymoma

prednisone has been researched along with Thymoma in 88 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)

Research Excerpts

ExcerptRelevanceReference
"To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG)."5.34Minimal manifestation status and prednisone withdrawal in the MGTX trial. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, G; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Heckmann, JM; Jackson, CE; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BRF; Lee, I; Massey, JM; McPherson, T; Minisman, G; Mozaffar, T; Nix, W; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Sonett, JR; Ströbel, P; Sussman, J; Tandan, R; Verschuuren, JJG; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2020)
"To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis."3.72Development of generalized disease at 2 years in patients with ocular myasthenia gravis. ( Homel, P; Kupersmith, MJ; Latkany, R, 2003)
"A case of invasive thymoma is presented showing tumour regression after palliative treatment with prednisone."3.71Regression of invasive thymoma following corticosteroid therapy. ( Mravunac, M; Termeer, A; Visser, FJ, 2001)
"In a 43-year-old woman, pancytopenia accompanying thymoma persisted after thymectomy, requiring weekly blood transfusions, and did not respond to prednisone 50 mg/day."3.69Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report. ( De Giacomo, T; Flaishman, I; Rendina, EA; Ricci, C; Venuta, F, 1995)
"The authors describe a 62-year-old man with a malignant thymoma that was clinically responsive to oral prednisone."3.68Nocardiosis after corticosteroid therapy for malignant thymoma. ( Borges, AA; Cohen, MH; Krasnow, SH; Wadleigh, RG, 1993)
"One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration."3.67Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. ( Coslett, HB; Johns, TR; Pascuzzi, RM, 1984)
"The authors report the case of a patient with malignant thymoma unresponsive to combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] and cisplatin/VP-16) who subsequently achieved clinical response to continuous daily prednisone."3.67Chemotherapy of malignant thymoma. Case report and review of the literature. ( Hu, E; Levine, J, 1986)
" Degree of weakness, duration of illness, use of prednisone, and history of thymectomy or thymoma did not affect the response to intravenous immunoglobulin."3.67High-dose intravenous immunoglobulin in the management of myasthenia gravis. ( Arsura, EL; Bick, A; Brunner, NG; Grob, D; Namba, T, 1986)
"Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma."3.66Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980)
"Thymomas and thymic carcinoma are rare neoplasms."2.43Current chemotherapy options for thymic epithelial neoplasms. ( Papadopoulos, KP; Thomas, CR, 2005)
"It may also be secondary to systemic lupus erythematosus, rheumatoid arthritis, acute severe renal failure, severe nutritional deficiency, or diverse neoplasms, and may remit with treatment of the primary condition."2.35Diagnosis and treatment of pure red cell aplasia. ( Krantz, SB, 1976)
"Thymectomy is considered an effective treatment for myasthenia gravis but the benefit is not immediate."1.56[Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients]. ( Alba-Isasi, MT; Arroyo-Tristán, A; Cabrera-Maqueda, JM; Hernández, R; Morales-Ortiz, A, 2020)
"His labs were consistent with autoimmune haemolytic anaemia (AIHA), except his reticulocyte count was unexpectedly low."1.56Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection. ( Atkinson, TS; Chaaya, G; Jetly-Shridhar, R; Xie, J, 2020)
"Thymoma is a rare tumor which represents about 20% of mediastinal tumors."1.35[Thymoma associated with pure red cell aplasia and Kaposi's sarcoma]. ( Ayoub, A; Ben Amira, S; Fouzi, S; Ketata, W; Msaad, S; Yangui, I, 2009)
"Hypereosinophilia has been associated with a wide variety of systemic disorders, including myositis."1.33Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. ( Avni, I; Buchman, AS; Sadeh, M; Sharabi, Y, 2006)
" Remission, pharmacological remission, and marked improvement with reduction in drug dosage were considered good results."1.31Clinical characteristics and prognosis of myasthenia gravis in older people. ( Batocchi, AP; Di Schino, C; Evoli, A; Minisci, C; Tonali, P, 2000)
"Thymomas are rare neoplasms that are usually associated with parathymic syndromes, pure red cell aplasia, myasthenia gravis, hypogammaglobulinaemia and other mainly immunological disorders."1.30Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. ( Bianco, AR; Lastoria, S; Lombardi, G; Martignetti, A; Montella, L; Palmieri, G; Salvatore, M, 1999)
"Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival."1.29Thymoma. A retrospective study of 87 cases. ( Cox, JD; Hong, WK; Komaki, R; Lee, JS; Park, HS; Pollack, A; Putnam, JB; Shin, DM, 1994)
"Distant metastases and chemotherapy in malignant thymoma are reviewed."1.27Malignant thymoma with distant metastases: a case report and review of the literature. ( Ichino, Y; Ishikawa, T; Obuchi, M; Suko, K, 1983)
"Oral Prednisone was nearly always preferred: alternate-day high single dose (75 to 115 mg) has given good results in most cases even if in some cases a small dose was required in the "off day"; inversely a lower alternate-day or daily dose was often sufficient."1.26Treatment of myasthenia gravis. Report on 139 patients. ( Crucitti, F; David, P; Evoli, A; Scoppetta, C; Tonali, P; Vaccario, ML, 1979)
"Four patients suffering spinal cord compression resulting from epidural metastases were treated with adrenocorticosteroid hormones."1.26"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. ( Cvitkovic, E; Howieson, J; Posner, JB, 1977)
" Radical excision of the tumor, if possible, and the remaining thymus, high dosage alternate day prednisone, and radiation therapy, if indicated, seem the treatments of choice."1.25Myasthenia gravis and invasive thymoma: a 20-year experience. ( Brown, WJ; Goldman, AJ; Herrmann, C; Keesey, JC; Mulder, DG, 1975)

Research

Studies (88)

TimeframeStudies, this research(%)All Research%
pre-199043 (48.86)18.7374
1990's13 (14.77)18.2507
2000's18 (20.45)29.6817
2010's9 (10.23)24.3611
2020's5 (5.68)2.80

Authors

AuthorsStudies
Wang, S1
Yang, H1
Guo, R1
Wang, L1
Zhang, Y4
Lv, J2
Zhao, X2
Zhang, J2
Fang, H2
Zhang, Q2
Yang, J2
Cui, X2
Gao, P1
Chang, T1
Gao, F2
Cabrera-Maqueda, JM1
Alba-Isasi, MT1
Hernández, R1
Arroyo-Tristán, A1
Morales-Ortiz, A1
Xie, J1
Chaaya, G1
Jetly-Shridhar, R1
Atkinson, TS1
Yuen, C1
Soliven, B1
Rezania, K1
Lee, I1
Kuo, HC1
Aban, IB1
Cutter, GR1
McPherson, T1
Kaminski, HJ1
Sussman, J1
Ströbel, P2
Oger, J2
Cea, G1
Heckmann, JM1
Evoli, A5
Nix, W1
Ciafaloni, E1
Antonini, G1
Witoonpanich, R1
King, JO1
Beydoun, SR1
Chalk, CH1
Barboi, AC1
Amato, AA1
Shaibani, AI1
Katirji, B1
Lecky, BRF1
Buckley, C1
Vincent, A1
Dias-Tosta, E1
Yoshikawa, H1
Waddington-Cruz, M1
Pulley, MT1
Rivner, MH1
Kostera-Pruszczyk, A1
Pascuzzi, RM2
Jackson, CE1
Verschuuren, JJG1
Massey, JM1
Kissel, JT1
Werneck, LC1
Benatar, M1
Barohn, RJ1
Tandan, R3
Mozaffar, T1
Conwit, R1
Minisman, G1
Sonett, JR1
Wolfe, GI1
Nakamura, S1
Kawaguchi, K1
Fukui, T1
Hakiri, S1
Ozeki, N1
Mori, S1
Goto, M1
Hashimoto, K1
Ito, T1
Yokoi, K1
Li, M1
Han, J1
Ren, L1
Li, Q1
Du, Y1
Weissferdt, A1
Moran, CA1
Benjamin, B1
Zaltzman, R1
Shpitz, B1
Gordon, CR1
Avital, S1
Modrego, PJ1
Arribas, J1
Sudulagunta, SR1
Sepehrar, M1
Sodalagunta, MB1
Settikere Nataraju, A1
Bangalore Raja, SK1
Sathyanarayana, D1
Gummadi, S1
Burra, HK1
Kirzinger, L1
Boy, S1
Marienhagen, J1
Schuierer, G1
Neu, R1
Ried, M1
Hofmann, HS1
Wiebe, K1
May, C1
Kleylein-Sohn, J1
Baierlein, C1
Bogdahn, U1
Marx, A1
Schalke, B1
Ketata, W1
Fouzi, S1
Msaad, S1
Ben Amira, S1
Yangui, I1
Ayoub, A1
Rigamonti, A1
Lauria, G1
Piamarta, F1
Fiumani, A1
Agostoni, E1
Burrough, ER1
Myers, RK1
Hostetter, SJ1
Fox, LE1
Bayer, BJ1
Felz, CL1
Waller, KR1
Whitley, EM1
Katzberg, HD1
Aziz, T1
Kupersmith, MJ1
Latkany, R1
Homel, P1
PARRY, EH1
KILPATRICK, GS1
HARDISTY, RM1
ADAMS, JE1
KLEIN, JJ1
GOTTLIEB, AJ1
MONES, RJ1
APPEL, SH1
OSSERMAN, KE1
ROSNER, P1
HAUSSER, E1
Greenberg, SA1
Loehrer, PJ1
Wang, W1
Johnson, DH1
Aisner, SC1
Ettinger, DS1
Zieliński, M1
Kuzdzał, J1
Staniec, B1
Harazda, M1
Nabiałek, T1
Pankowski, J1
Szlubowski, A1
Medoń, J1
Tiseo, M1
Monetti, F1
Ferrarini, M1
Serrano, J1
Chiaramondia, M1
Ardizzoni, A1
Papadopoulos, KP1
Thomas, CR1
Ji, H1
Zhang, WY1
Liu, WP1
Li, GD1
Li, L1
Avni, I1
Sharabi, Y1
Sadeh, M1
Buchman, AS1
Yamato, H1
Tsutsumi, Y1
Ehira, N1
Kanamori, H1
Shimoyama, N1
Tanaka, J1
Imamura, M1
Asaka, M1
Hasegawa, T1
Masauzi, N1
van der Marel, J1
Pahlplatz, PV1
Steup, WH1
Hendriks, ER1
Fattorossi, A1
Battaglia, A1
Buzzonetti, A1
Minicuci, G1
Riso, R1
Peri, L1
Scambia, G1
Ezzie, ME1
Janssen, WJ1
O'Brien, JM1
Fox, CC1
Schwarz, MI1
Schumm, F1
Brinkmann, A1
Fateh-Moghadam, A1
Almog, C2
Horowitz, M1
Burke, M1
Ichino, Y1
Obuchi, M1
Suko, K1
Ishikawa, T1
Coslett, HB1
Johns, TR1
Tonali, P3
Scoppetta, C2
David, P2
Daugaard, G1
Hansen, HH1
Rørth, M1
Evans, WK1
Thompson, DM1
Simpson, WJ1
Feld, R1
Phillips, MJ1
Park, HS1
Shin, DM1
Lee, JS1
Komaki, R1
Pollack, A1
Putnam, JB1
Cox, JD1
Hong, WK1
Kaseda, S1
Horinouchi, H1
Kato, R1
Kobayashi, K1
Borges, AA1
Krasnow, SH1
Wadleigh, RG1
Cohen, MH1
De Giacomo, T1
Rendina, EA1
Venuta, F1
Flaishman, I1
Ricci, C1
Palmieri, G3
Lastoria, S3
Colao, A1
Vergara, E1
Varrella, P1
Biondi, E1
Selleri, C1
Catalano, L1
Lombardi, G2
Bianco, AR2
Salvatore, M2
Beekman, R1
Kuks, JB1
Oosterhuis, HJ1
Rennenberg, RJ1
Pauwels, P1
Vlasveld, LT1
Kodama, K1
Doi, O1
Higashiyama, M1
Yokouchi, H1
Yasuda, T1
Funai, H1
Fuxiang, G1
Beutner, EH1
Montella, L2
Martignetti, A1
Herrmann, DN1
Blaivas, M1
Wald, JJ1
Feldman, EL1
Batocchi, AP1
Minisci, C1
Di Schino, C1
Termeer, A1
Visser, FJ1
Mravunac, M1
Crucitti, F1
Vaccario, ML1
Dawkins, RL1
Posner, JB1
Howieson, J1
Cvitkovic, E1
Pik, A1
Weisberg, D1
Herczeg, E1
Kurstjens, R1
Haanen, C1
Shellito, J1
Khandekar, JD1
McKeever, WP1
Vick, NA1
Krantz, SB3
Waldmann, TA1
Broder, S1
Krakauer, R1
MacDermott, RP1
Durm, M1
Goldman, C1
Meade, B1
Goldman, AJ2
Hermann, C1
Keesey, J1
Mulder, DG2
Brown, WJ2
Herrmann, C1
Keesey, JC1
Doll, DC1
Landreneau, RJ1
List, AF1
Koopman, WJ1
Taylor, R2
DiCostanzo, DP2
Sharma, K2
Fries, T2
Roberts, J2
Ramon, P2
Wallaert, B2
Lemaître, L1
Fournier, E1
Rémy, J1
Bart, F1
Gosselin, B2
Tonnel, AB1
Wurtz, A1
Chambon, JP1
Göldel, N2
Böning, L2
Fredrik, A1
Hölzel, D1
Hartenstein, R1
Wilmanns, W2
Hu, E1
Levine, J1
Frederik, A1
Arsura, EL1
Bick, A1
Brunner, NG1
Namba, T1
Grob, D1
Donovan, PJ1
Foley, JF1
Tominaga, S1
Kondo, M1
Ando, Y1
Yamashita, S1
Uematsu, M1
Shigematsu, N1
Nishiguchi, I1
Hashimoto, S1
MacKechnie, HL1
Squires, AH1
Platts, M1
Pruzanski, W1
Tan, RS1
River, GL1
Selecky, PA1
Ziment, I1
Krain, LS1
Bierman, SM1
Vasavada, PJ1
Bournigal, LJ1
Reynolds, RW1
Green, JD1
Forman, WH1
Doll, R1
Kinlen, L1
Dawson, MA1
Böttcher, D1
Maas, D1
Wendt, F2
Schubothe, H2
Safdar, SH1
Brown, EB1
Doyen, A1
Schoop, W1
Hunstein, W1
Fliedner, TM1
Wedler, HW1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone[NCT00294658]Phase 3126 participants (Actual)Interventional2006-06-30Completed
Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size[NCT00332969]Phase 225 participants (Actual)Interventional2005-09-30Completed
Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma[NCT00003283]Phase 238 participants (Anticipated)Interventional1998-10-13Completed
Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.[NCT00619671]Phase 1/Phase 210 participants (Anticipated)Interventional2004-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Azathioprine Use

(NCT00294658)
Timeframe: baseline to 3 years

Interventionparticipants (Number)
Thymectomy Plus Prednisone11
Prednisone Alone28

Cumulative Days in Hospital for Myasthenia Gravis Exacerbation

Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=17 (out of 60) (NCT00294658)
Timeframe: baseline to 2 years

Interventiondays (Mean)
Thymectomy Plus Prednisone5.5
Prednisone Alone26.4

Cumulative Days in Hospital for Myasthenia Gravis Exacerbation

Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=22 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years

Interventiondays (Mean)
Thymectomy Plus Prednisone8.7
Prednisone Alone22.5

Cumulative Number of Hospital Days

Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years

Interventiondays (Mean)
Thymectomy Plus Prednisone8.4
Prednisone Alone19.2

Intravenous Immunoglobulin Use

(NCT00294658)
Timeframe: baseline to 3 years

Interventionparticipants (Number)
Thymectomy Plus Prednisone11
Prednisone Alone23

Number of Patients With at Least One Serious Adverse Events

Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years

Interventionparticipants (Number)
Thymectomy Plus Prednisone25
Prednisone Alone33

Number of Serious Adverse Events

Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years

Interventionevents (Number)
Thymectomy Plus Prednisone48
Prednisone Alone93

Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 1: Penalized Using Maximum Dose Before Azathioprine)

For each participant who took azathioprine, we penalized them by taking the maximum dose of prednisone before azathioprine was added. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

Interventionmg (Mean)
Thymectomy Plus Prednisone34.4
Prednisone Alone64.4

Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 2: Penalized Using Dose at Time of Starting Azathioprine)

For each participant who took azathioprine, we penalized them by taking the prednisone dose at the time azathioprine commenced. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months

Interventionmg (Mean)
Thymectomy Plus Prednisone33.3
Prednisone Alone57.9

Plasma Exchange Use

(NCT00294658)
Timeframe: baseline to 3 years

Interventionparticipants (Number)
Thymectomy Plus Prednisone10
Prednisone Alone9

Time-weighted Average Alternate-day Prednisone Dose (mg) Measured Over 3 Years

Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months

Interventionmg (Mean)
Thymectomy Plus Prednisone32
Prednisone Alone54

Time-Weighted Average MG Activity of Daily Living (MG-ADL)

MG Activity of Daily Living total scores range from 0 to 24, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: baseline, month 4, 6 and every 3 months through 36 months

Interventionunits on a scale (Mean)
Thymectomy Plus Prednisone2.24
Prednisone Alone3.41

Time-weighted Average Prescribed Alternate Day Prednisone Dose (mg)

Physicians reported prescribed alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prescribed prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline-day 20, month 1,2, 3, 4, 6 and every 3 months through 36 months

Interventionmg (Mean)
Thymectomy Plus Prednisone34.3
Prednisone Alone55.6

Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years

Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. The time weighted average is a calculation that provides an integrated measure of the outcome over the time of followup. The denominator that was used to compute the time-weighted average for the Quantitative Myasthenia Gravis (QMG) score and the prednisone dose was the number of days from randomization to the last visit. Computations used the trapezoidal method where in the QMG score is multiplied by the number of days at this level from one visit to the next and added up over the entire followup experience and divided by the total number of days from randomization. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

Interventionunits on a scale (Mean)
Thymectomy Plus Prednisone6.15
Prednisone Alone8.99

Classification of Serious Adverse Events

(NCT00294658)
Timeframe: baseline to 3 years

,
Interventionparticipants (Number)
Life-threateningDisability or incapacityMedical or surgical interventionDeathComplication due to thytmectomyHospitalization
Prednisone Alone7251031
Thymectomy Plus Prednisone1890115

Hospitalization for Exacerbation of Myasthenia Gravis

(NCT00294658)
Timeframe: baseline to 2 years and baseline to 3 years

,
Interventionparticipants (Number)
Months 0-24Months 0-36
Prednisone Alone1722
Thymectomy Plus Prednisone66

Minimal Manifestation (MM) Status at Month 12, 24 and 36

Number of participants who were in minimal manifestation status at month 12, 24 and 36. (NCT00294658)
Timeframe: Month 12, 24 and 36

,
Interventionparticipants (Number)
Month 12Month 24Month 36
Prednisone Alone202024
Thymectomy Plus Prednisone413939

Reason for Hospitalization According to Medical Dictionary for Regulatory Activities Term

Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years

,
Interventionevents (Number)
Gastrointestinal disorderHepatobiliary disorderInfection or infestationInjury, poisoning, or procedure complicationMetabolism or nutrition disorderNervous system disorderRespiratory, thoracic, or mediastinal disorderSurgical or medical procedureVascular disorder
Prednisone Alone2170022271
Thymectomy Plus Prednisone204218100

Short Form-36 Standardized Mental Component

Range from 0 to 100, the higher the mental component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36

,
Interventionunits on a scale (Median)
Month 0Month 12Month 24Month 36
Prednisone Alone46.241.746.748.2
Thymectomy Plus Prednisone49.139.149.951.7

Short Form-36 Standardized Physical Component

Range from 0 to 100, the higher the physical component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36

,
Interventionunits on a scale (Median)
Month 0Month 12Month 24Month 36
Prednisone Alone37.944.443.044.2
Thymectomy Plus Prednisone41.448.450.348.2

Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Prednisone Use at Enrollment

Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionmg (Mean)
Not prednisone naïvePrednisone naïve
Prednisone Alone5645
Thymectomy Plus Prednisone3525

Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Sex

Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionmg (Mean)
FemaleMale
Prednisone Alone5455
Thymectomy Plus Prednisone3331

Subgroup Analyses of Time-weighted Average Average Alternate-day Prednisone Dose (mg) by Age at Disease Onset

Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionmg (Mean)
Age (Years) at Disease Onset < 40Age (Years) at Disease Onset ≥ 40
Prednisone Alone5549
Thymectomy Plus Prednisone3527

Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Age at Disease Onset

Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionunits on a scale (Mean)
Age (years) at Disease Onset < 40Age (years) at Disease Onset ≥ 40
Prednisone Alone9.607.85
Thymectomy Plus Prednisone6.505.33

Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Prednisone Use at Enrollment

Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionunits on a scale (Mean)
Not prednisone naïvePrednisone naïve
Prednisone Alone9.108.84
Thymectomy Plus Prednisone6.305.66

Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Sex

Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months

,
Interventionunits on a scale (Mean)
FemaleMale
Prednisone Alone9.737.45
Thymectomy Plus Prednisone6.475.23

Time-Weighted Average MG Activity of Daily Living (MG-ADL) at Month 12, 24, and 36

MG Activity of Daily Living total scores range from 0 to 24 by visit, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: Month 12, 24, and 36

,
Interventionunits on a scale (Mean)
Month 12Month 24Month 36
Prednisone Alone3.333.112.69
Thymectomy Plus Prednisone1.922.022.14

Treatment Associated Complications (TAC)

Treatment associated complications measured complications occurred by myasthenia gravis patients. Report number of participant with at least one complications by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36

,
InterventionParticipants (Count of Participants)
Month 0Month 1Month 2Month 3Month 4Month 6Month 9Month 12Month 15Month 18Month 21Mpnth 24Mpnth 27Month 30Month 33Month 36
Prednisone Alone17152016232226282424202317192323
Thymectomy Plus Prednisone22152221232137352928222825232423

Treatment Associated Symptoms (TAS)

Treatment associated symptoms measured myasthenia gravis symptoms such as back pain and/or bruises. Report number of participant with at least one treatment associated symptoms by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36

,
InterventionParticipants (Count of Participants)
Month 0Month 1Month 2Month 3Month 4Month 6Month 9Month 12Month 15Month 18Month 21Mpnth 24Mpnth 27Month 30Month 33Month 36
Prednisone Alone53525354545350525151505150504847
Thymectomy Plus Prednisone63556160596059565652525250495149

Reviews

6 reviews available for prednisone and Thymoma

ArticleYear
Current chemotherapy options for thymic epithelial neoplasms.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cisplatin; Combined Modality Therapy; Diseas

2005
A case of thymoma-associated autoimmune haemolytic anaemia.
    The Netherlands journal of medicine, 1997, Volume: 50, Issue:3

    Topics: Administration, Oral; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Hormonal; Coombs Test; F

1997
[Thymoma and somatostatin analogs. Biology, diagnostic and clinical practice].
    Minerva endocrinologica, 2001, Volume: 26, Issue:3

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Indium Radi

2001
Diagnosis and treatment of pure red cell aplasia.
    The Medical clinics of North America, 1976, Volume: 60, Issue:5

    Topics: Acute Kidney Injury; Anemia, Aplastic; Antilymphocyte Serum; Arthritis, Rheumatoid; Blood Cell Count

1976
Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy.
    Cancer, 1990, Mar-15, Volume: 65, Issue:6

    Topics: Drug Administration Schedule; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisone; Pyridostig

1990
Annotation: pure red cell aplasia.
    British journal of haematology, 1973, Volume: 25, Issue:1

    Topics: Adult; Anemia, Aplastic; Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Bone Marrow; Bo

1973

Trials

3 trials available for prednisone and Thymoma

ArticleYear
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
    Neurology, 2020, 08-11, Volume: 95, Issue:6

    Topics: Adolescent; Adult; Animals; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Mal

2020
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Prepa

2016
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcin

2004

Other Studies

79 other studies available for prednisone and Thymoma

ArticleYear
Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Age of Onset; Aged; Agrin; Autoantibodies; Autoantigens; China; Cholinesterase Inhibitors; Female; G

2021
[Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients].
    Revista de neurologia, 2020, Mar-16, Volume: 70, Issue:6

    Topics: Acetylcholine; Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Combined Modality Thera

2020
Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection.
    BMJ case reports, 2020, Mar-18, Volume: 13, Issue:3

    Topics: Adult; Anemia, Hemolytic, Autoimmune; Diagnosis, Differential; Erythrocyte Transfusion; Glucocortico

2020
ATM mutation in a patient with thymoma-associated myasthenia gravis.
    Muscle & nerve, 2020, Volume: 62, Issue:2

    Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholinesterase

2020
Multimodality therapy for thymoma patients with pleural dissemination.
    General thoracic and cardiovascular surgery, 2019, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine;

2019
Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.
    European journal of neurology, 2019, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Autoantibodies; Child; Child, Preschool; China; Cholinesterase

2019
The impact of neoadjuvant chemotherapy on the histopathological assessment of thymomas: a clinicopathological correlation of 28 cases treated with a similar regimen.
    Lung, 2013, Volume: 191, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cycl

2013
Presacral Mass Discovered during Pregnancy followed by Myasthenia Gravis.
    The Israel Medical Association journal : IMAJ, 2015, Volume: 17, Issue:5

    Topics: Adult; Azathioprine; Castleman Disease; Cholinesterase Inhibitors; Female; Humans; Immunosuppressive

2015
Spontaneous resolution of a mediastinal mass in a woman with myasthenia gravis.
    Neurologia, 2018, Volume: 33, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azathioprine; Cholinesterase Inhib

2018
Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
    German medical science : GMS e-journal, 2016, Volume: 14

    Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Antibodies; Diabetes Complications; Diabetes Me

2016
[Thymoma associated with pure red cell aplasia and Kaposi's sarcoma].
    Revue des maladies respiratoires, 2009, Volume: 26, Issue:1

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr

2009
Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
    Journal of the neurological sciences, 2011, Mar-15, Volume: 302, Issue:1-2

    Topics: Action Potentials; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Electric Stimulation; Evo

2011
Amyloid deposition in 2 feline thymomas.
    Veterinary pathology, 2012, Volume: 49, Issue:4

    Topics: Amyloid; Animals; Cat Diseases; Cats; Female; Immunosuppressive Agents; Male; Mediastinal Neoplasms;

2012
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes.
    Journal of the neurological sciences, 2002, Oct-15, Volume: 202, Issue:1-2

    Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Cell Culture Techniques; Cholinesterase Inhibitors;

2002
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Archives of neurology, 2003, Volume: 60, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodi

2003
Red-cell aplasia and benign thymoma; studies on a case responding to prednisone.
    British medical journal, 1959, May-02, Volume: 1, Issue:5130

    Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Thymoma

1959
LEUKEMOGENIC THYMOMA: REPORT OF A UNIQUE CASE.
    American journal of clinical pathology, 1963, Volume: 40

    Topics: Adolescent; Bone Marrow; Chlorothiazide; Humans; Leukemia; Mediastinal Neoplasms; Neoplasm Metastasi

1963
THYMOMA AND POLYMYOSITIS. ONSET OF MYASTHENIA GRAVIS AFTER THYMECTOMY: REPORT OF TWO CASES.
    Archives of internal medicine, 1964, Volume: 113

    Topics: Aspartate Aminotransferases; Autoimmune Diseases; Biopsy; Cortisone; Electromyography; Humans; Myast

1964
[PURE ERYTHROBLASTOPENIA. APROPOS OF A CASE OF PRIMARY PURE ERYTHROBLASTOPENIA IN AN ADULT].
    La Presse medicale, 1964, Dec-19, Volume: 72

    Topics: Anemia; Anemia, Aplastic; Classification; Diagnosis, Differential; Geriatrics; Humans; Prednisone; R

1964
Acquired rippling muscle disease with myasthenia gravis.
    Muscle & nerve, 2004, Volume: 29, Issue:1

    Topics: Adult; Alopecia Areata; Antineoplastic Agents; Electromyography; Humans; Male; Muscle Contraction; M

2004
Safety for preoperative use of steroids for transsternal thymectomy in myasthenia gravis.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2004, Volume: 26, Issue:2

    Topics: Adult; Female; Humans; Male; Morbidity; Myasthenia Gravis; Postoperative Complications; Prednisone;

2004
CASE 1. Complete remission to corticosteroids in an octreotide-refractory thymoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-01, Volume: 23, Issue:7

    Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Humans; Middle Aged; Octreotide;

2005
[Mediastinal (thymic) large B-cell lymphoma: three cases reports].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2005, Volume: 34, Issue:5

    Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diffe

2005
Eosinophilia, myositis, and myasthenia gravis associated with a thymoma.
    Muscle & nerve, 2006, Volume: 34, Issue:2

    Topics: Aged; Anti-Inflammatory Agents; Blood Cell Count; Cholinesterase Inhibitors; Eosinophilia; Eye Movem

2006
A case of non-Hodgkin's lymphoma and invasive thymoma treated with R-CHOP therapy.
    International journal of hematology, 2006, Volume: 83, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C

2006
Thymoma with paraneoplastic syndromes, Good's syndrome, and pure red cell aplasia.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4

    Topics: Agammaglobulinemia; Biopsy, Needle; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Ag

2007
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.
    Journal of clinical immunology, 2008, Volume: 28, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antigens, CD; CD3 Complex; CD4 Lymphocyte Count; C

2008
Clinical problem-solving. Failure to respond--a 52-year-old man presented to his primary care physician with dyspnea and cough.
    The New England journal of medicine, 2008, Jan-03, Volume: 358, Issue:1

    Topics: Anti-Bacterial Agents; Bacteremia; Cough; Diagnosis, Differential; Dyspnea; Glucocorticoids; Humans;

2008
[Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
    Deutsche medizinische Wochenschrift (1946), 1984, Aug-17, Volume: 109, Issue:33

    Topics: Acetylcholine; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclophosph

1984
Steroid therapy in inappropriate secretion of antidiuretic hormone due to malignant thymoma.
    Respiration; international review of thoracic diseases, 1983, Volume: 44, Issue:5

    Topics: Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Rad

1983
Malignant thymoma with distant metastases: a case report and review of the literature.
    Japanese journal of clinical oncology, 1983, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; F

1983
Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.
    Annals of neurology, 1984, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Drug Administration Schedule; Female; Humans; Male; Mid

1984
Myasthenia gravis in the elderly: report of 37 cases.
    Journal of the American Geriatrics Society, 1983, Volume: 31, Issue:6

    Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Pyridosti

1983
Combination chemotherapy for malignant thymoma.
    Annals of internal medicine, 1983, Volume: 99, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl

1983
Combination chemotherapy in invasive thymoma role of COPP.
    Cancer, 1980, Oct-01, Volume: 46, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Co

1980
Thymoma. A retrospective study of 87 cases.
    Cancer, 1994, May-15, Volume: 73, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

1994
[Treatment of invasive thymoma using low dose and extended-field irradiation including hemi-thorax or whole-thorax].
    Kyobu geka. The Japanese journal of thoracic surgery, 1993, Volume: 46, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali

1993
Nocardiosis after corticosteroid therapy for malignant thymoma.
    Cancer, 1993, Mar-01, Volume: 71, Issue:5

    Topics: Anti-Inflammatory Agents; Bacteremia; Humans; Hydrocortisone; Immunocompromised Host; Male; Middle A

1993
Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report.
    Scandinavian journal of thoracic and cardiovascular surgery, 1995, Volume: 29, Issue:3

    Topics: Adult; Blood Transfusion; Cyclosporine; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosu

1995
Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone.
    The New England journal of medicine, 1997, Jan-23, Volume: 336, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Middle

1997
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.
    Journal of neurology, 1997, Volume: 244, Issue:2

    Topics: Age of Onset; Aged; Autoimmune Diseases; Azathioprine; Cholinesterase Inhibitors; Cohort Studies; Di

1997
Dramatic response of postthymomectomy myasthenia gravis with multiple lung nodules to corticosteroids.
    The Annals of thoracic surgery, 1997, Volume: 64, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Fem

1997
Pemphigus erythematosus associated with thymoma: a case report.
    Cutis, 1999, Volume: 64, Issue:3

    Topics: Cicatrix; Dapsone; Drug Therapy, Combination; Humans; Male; Middle Aged; Pemphigus; Postoperative Co

1999
Role of somatostatin analogue-based therapy in unresponsive malignant thymomas.
    Annals of medicine, 1999, Volume: 31 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasm Staging;

1999
Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma.
    Muscle & nerve, 2000, Volume: 23, Issue:7

    Topics: Adult; Anti-Inflammatory Agents; Granuloma; Humans; Liver Cirrhosis, Biliary; Male; Muscle, Skeletal

2000
Clinical characteristics and prognosis of myasthenia gravis in older people.
    Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Cholinesterase Inhibitors; Drug The

2000
Regression of invasive thymoma following corticosteroid therapy.
    The Netherlands journal of medicine, 2001, Volume: 58, Issue:4

    Topics: Adult; Antineoplastic Agents, Hormonal; Humans; Male; Prednisone; Remission Induction; Thymoma; Thym

2001
Treatment of myasthenia gravis. Report on 139 patients.
    Journal of neurology, 1979, Volume: 222, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Female; Follow-Up Studies; Humans; Male

1979
Polymyositis and dermatomyositis: clinical problems.
    Australian and New Zealand journal of medicine, 1978, Volume: 8 Suppl 1

    Topics: Collagen Diseases; Dermatomyositis; Diagnosis, Differential; Humans; Myasthenia Gravis; Myositis; Ne

1978
"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases.
    Annals of neurology, 1977, Volume: 2, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Dysgerminoma; Epidural Space; Humans;

1977
Regression of malignant thymoma with metastases after treatment with adrenocortical steroids.
    Israel journal of medical sciences, 1978, Volume: 14, Issue:4

    Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Thymoma; Thymus Neoplasms

1978
[Remission of pure red cell aplasia obtained by splenectomy after failure of thymomectomy and immunosuppressive treatment].
    Nederlands tijdschrift voor geneeskunde, 1978, Aug-19, Volume: 122, Issue:33

    Topics: Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Erythropoiesis; Humans; Immuno

1978
Invasive thymoma responsive to oral corticosteroids.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Administration, Oral; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Pleural

1978
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.
    Federation proceedings, 1976, Volume: 35, Issue:9

    Topics: Agammaglobulinemia; Antibody Formation; Antibody-Producing Cells; B-Lymphocytes; Cell Differentiatio

1976
Invasive thymoma and myasthenia gravis: a twenty-year experience.
    Transactions of the American Neurological Association, 1975, Volume: 100

    Topics: Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Thymectomy; Thymoma; Thymus Neopla

1975
Myasthenia gravis and invasive thymoma: a 20-year experience.
    Neurology, 1975, Volume: 25, Issue:11

    Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; N

1975
Malignant thymoma associated with peripheral T-cell lymphocytosis.
    Medical and pediatric oncology, 1991, Volume: 19, Issue:6

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modal

1991
Myasthenia gravis.
    Axone (Dartmouth, N.S.), 1990, Volume: 11, Issue:4

    Topics: Adult; Aged; Female; Humans; Male; Myasthenia Gravis; Prednisone; Thymoma

1990
[Value of x-ray computed tomography in assessing the extent of invasive lympho-epithelial thymoma in the adult. Therapeutic implications].
    Revue des maladies respiratoires, 1986, Volume: 3, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined

1986
[Invasive thymoma with pulmonary metastasis. Complete remission 5 years after surgery and chemotherapy using the CHOP-BLEO protocol].
    Revue des maladies respiratoires, 1988, Volume: 5, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin

1988
Chemotherapy of invasive thymoma. A retrospective study of 22 cases.
    Cancer, 1989, Apr-15, Volume: 63, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality

1989
Disseminated thymoma and myasthenia gravis: dramatic response to prednisone.
    Annals of neurology, 1989, Volume: 25, Issue:2

    Topics: Combined Modality Therapy; Female; Humans; Middle Aged; Myasthenia Gravis; Neoplasm Metastasis; Pred

1989
Chemotherapy of malignant thymoma. Case report and review of the literature.
    Cancer, 1986, Mar-15, Volume: 57, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide;

1986
[Successful chemotherapy of a metastatic malignant thymoma].
    Deutsche medizinische Wochenschrift (1946), 1987, Sep-11, Volume: 112, Issue:37

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Female; Hum

1987
High-dose intravenous immunoglobulin in the management of myasthenia gravis.
    Archives of internal medicine, 1986, Volume: 146, Issue:7

    Topics: Adult; Aged; Autoantibodies; Blood Proteins; Drug Therapy, Combination; Female; Humans; Infusions, P

1986
Chemotherapy in invasive thymomas: five case reports.
    Journal of surgical oncology, 1986, Volume: 33, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Doxorubicin; Female;

1986
[Full-dose CHOP chemotherapy--feasibility and influence upon radiotherapy].
    Nihon Gan Chiryo Gakkai shi, 1985, Aug-20, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1985
Thymoma, myasthenia gravis, erythroblastopenic anemia and systemic lupus erythematosus in one patient.
    Canadian Medical Association journal, 1973, Oct-20, Volume: 109, Issue:8

    Topics: Ambenonium Chloride; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Bronchop

1973
Thymoma, acquired hypogammaglobulinaemia, lichen planus, alopecia areata.
    Proceedings of the Royal Society of Medicine, 1974, Volume: 67, Issue:3

    Topics: Agammaglobulinemia; Aged; Alopecia Areata; Ampicillin; Blood Transfusion; Bronchiectasis; Cytotoxici

1974
Erythroid aplasia following thymomectomy. Report of a case with a positive lupus erythematosus cell preparation and elevated plasma erythropoietin level.
    JAMA, 1966, Aug-29, Volume: 197, Issue:9

    Topics: Blood Transfusion; Bone Marrow; Erythropoiesis; Erythropoietin; Female; Humans; Mediastinal Neoplasm

1966
Prolonged respirator support for the treatment of intractable myasthenia gravis.
    Chest, 1974, Volume: 65, Issue:2

    Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Drug Therapy, Combination; Enteral Nutrition; Fem

1974
Pemphigus vulgaris and internal malignancy.
    Cancer, 1974, Volume: 33, Issue:4

    Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Dexamethasone; F

1974
Thymoma associated with pure red cell aplasia and hypogammaglobulinemia.
    Postgraduate medicine, 1973, Volume: 54, Issue:6

    Topics: Agammaglobulinemia; Aged; Anemia, Aplastic; Blood Cell Count; Blood Transfusion; Bone Marrow Examina

1973
Response of thymoma to steroids.
    Chest, 1974, Volume: 65, Issue:1

    Topics: Aged; Female; Humans; Mediastinal Neoplasms; Prednisone; Radiography; Thoracic Surgery; Thorax; Thym

1974
Immunosurveillance and cancer: epidemiological evidence.
    British medical journal, 1970, Nov-14, Volume: 4, Issue:5732

    Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Chediak-Higashi Syndrome; Child; Child, Preschoo

1970
Thymoma associated with pancytopenia and Hashimoto's thyroiditis.
    The American journal of medicine, 1972, Volume: 52, Issue:3

    Topics: Adolescent; Anemia, Aplastic; Bone Marrow; Cobalt Isotopes; Female; Humans; Prednisone; Stanozolol;

1972
[Anemia caused by erythroblastopenia in adult age].
    Klinische Wochenschrift, 1970, Jan-15, Volume: 48, Issue:2

    Topics: Aged; Analgesics; Anemia, Aplastic; Azathioprine; Blood Transfusion; Female; Heart Failure; Hepatiti

1970
Successful immunosuppressive treatment of erythroid aplasia appearing after thymectomy.
    British journal of haematology, 1970, Volume: 19, Issue:4

    Topics: Anemia, Aplastic; Antibodies, Antinuclear; Azathioprine; Bone Marrow; Cyclophosphamide; Erythropoies

1970
[Erythroblastophthisis in thymoma. Report on 2 observations with remission].
    Schweizerische medizinische Wochenschrift, 1965, Oct-30, Volume: 95, Issue:44

    Topics: Anemia, Aplastic; Female; Humans; Male; Middle Aged; Nandrolone; Prednisone; Thymectomy; Thymoma

1965